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DOI 10.1016/j.ccr.2009.12.040SUMMARYAF4 and ENL family proteins are frequently fusedwithMLL, and they comprise a higher order complex (desig-
nated AEP) containing the P-TEFb transcription elongation factor. Here, we show that AEP is normally
recruited to MLL-target chromatin to facilitate transcription. In contrast, MLL oncoproteins fused with AEP
components constitutively form MLL/AEP hybrid complexes to cause sustained target gene expression,
which leads to transformation of hematopoietic progenitors. Furthermore, MLL-AF6, an MLL fusion with
a cytoplasmic protein, does not form such hybrid complexes, but nevertheless constitutively recruits AEP
to target chromatin via unknown alternative mechanisms. Thus, AEP recruitment is an integral part of both
physiological and pathological MLL-dependent transcriptional pathways. Bypass of its normal recruitment
mechanisms is the strategy most frequently used by MLL oncoproteins.INTRODUCTION
Leukemia is a heterogeneous disease with distinctive biological
and clinical properties that are conferred by a variety of acquired
genetic mutations (Gilliland, 2002). Chromosomal translocations
of the MLL gene account for 5%–10% of acute leukemias and
are generally associated with poor prognosis (Daser and Rab-
bitts, 2004; Krivtsov and Armstrong, 2007; Pui et al., 2004).
MLL gene rearrangements create fusion genes that contain the
50 portion of MLL and the 30 portion of its fusion partner, whose
products cause sustained expression of MLL target genes and
consequent enhanced proliferation of hematopoietic progenitors
(Ayton and Cleary, 2003; Lavau et al., 1997; Cozzio et al., 2003).
The amino-terminal portion of MLL serves as a targeting unit to
direct MLL oncoprotein complexes to their target loci through
DNA binding (Ayton et al., 2004; Slany et al., 1998) and associa-
tion with menin and LEDGF (Yokoyama et al., 2005; Yokoyama
and Cleary, 2008), whereas the fusion partner portion servesSignificance
MLL is fused by chromosomal translocations in 5%–10% of ac
molecular composition and function. Recent studies show that
ENL, and AF9) associate in a higher-order complex containin
complex is biochemically distinct from the MLL histone methy
MLL target genes during physiologic gene expression. In acute
chromatin by covalent fusion of MLL with one of several comp
MLL fusion proteins, thereby representing a unifyingmechanism
molecular therapy.
198 Cancer Cell 17, 198–212, February 17, 2010 ª2010 Elsevier Inc.as an effecter unit that causes sustained transactivation (Cheung
et al., 2007; Lavau et al., 2000; DiMartino et al., 2000; 2002;
Slany et al., 1998; So and Cleary, 2002; 2003). To date, approx-
imately 50 different fusion partners have been reported to form
chimeric MLL oncoproteins (Huret et al., 2001). However, the
mechanisms underlying this molecular diversity have not been
revealed.
The AF4 and ENL protein families are the most frequent MLL
fusion partners, accounting for two-thirds of MLL-associated
leukemia incidence (Huret et al., 2001). The AF4 family
comprises four paralogous proteins, including AF4, AF5q31,
LAF4, and FMR2. The ENL family includes ENL and AF9 and
has structural homology to the yeast Anc1 protein. The members
of both protein families possess transactivation domains and
therefore are thought to be involved in transcriptional regulation
(Prasad et al., 1995; Ma and Staudt, 1996; Morrissey et al., 1997;
Slany et al., 1998). All but FMR2 have been reported to form
fusion genes with MLL in leukemia (Domer et al., 1993; Takiute leukemias to a variety of partner proteins (>50) of diverse
several of the more commonMLL fusion partners (e.g., AF4,
g transcription elongation factors. Here we show that this
ltransferase complex, but nevertheless normally present at
leukemias, the complex is constitutively recruited to target
lex components or noncovalent mechanisms used by other
forMLL-mediated leukemogenesis that can be targeted by
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AEP Complex in MLL-Associated Leukemiaet al., 1999; von Bergh et al., 2002; Iida et al., 1993; Nakamura
et al., 1993; Tkachuk et al., 1992). AF4 family proteins associate
with ENL family proteins and P-TEFb (Positive Transcription
Elongation Factor b) (Erfurth et al., 2004; Zeisig et al., 2005;
Bitoun et al., 2007; Mueller et al., 2007). P-TEFb is composed
of CDK9 and cyclin T1 (or cyclin T2) and is capable of phosphor-
ylating the carboxy-terminal domain (CTD) of RNA polymerase II
(RNAPII) and DSIF to facilitate transcriptional elongation (Saun-
ders et al., 2006; Peterlin and Price, 2006). AF4 functions as
a positive regulator of P-TEFb kinase (Bitoun et al., 2007), which,
in turn, controls the transactivation activity or stability of AF4 and
ENL family proteins. ENL family proteins also associate with
DOT1L (Bitoun et al., 2007; Mueller et al., 2007; Zhang et al.,
2006), the major histone methyltransferase responsible for the
H3K79 methylation mark (Jones et al., 2008), which is predomi-
nantly associated with actively transcribed genes (Steger et al.,
2008). It has been reported that DOT1L also associates with
MLL-AF10 and plays a critical role in its oncogenic transforma-
tion (Okada et al., 2005). However, the molecular roles of these
components in MLL-dependent leukemogenesis have not
been clearly defined.
In this study, we investigated the contributions of a higher
order complex containing AF4 and ENL family proteins with
P-TEFb in physiologic and pathologic MLL-dependent trans-
cription.
RESULTS
AF4 Forms a Higher Order Complex with AF5q31, ENL,
and P-TEFb in Hematopoietic Cells
To identify AF4-associated proteins in vivo, we biochemically
purified AF4 complexes from K562 cells using column chroma-
tography followed by immuno-affinity purification with a highly
specific anti-AF4 monoclonal antibody (Figure 1A). Mass spec-
trometry identified AF5q31, ENL, CDK9, and cyclin T1 in the puri-
fied materials (Figure 1B). Reciprocal immunoprecipitation (IP)
further confirmed that all five proteins compose an endogenous
bona fide complex (Figure 1C) consistent with previous observa-
tions (Erfurth et al., 2004, Zeisig et al., 2005; Bitoun et al., 2007;
Mueller et al., 2007). In gel filtration analysis, the AF4 complex
components codistributed in fractions that eluted at an average
mass of 0.8 MDa (Figure 1D). A similar complex was obtained
using a monoclonal antibody specific for AF5q31 in the immuno-
affinity step (see Figure S1A available with this article online).
However, neither purification process yielded other proteins
previously reported to interact with ENL (e.g., DOT1L and
AF10) (Zeisig et al., 2005; Bitoun et al., 2007; Mueller et al.,
2007). These data demonstrate that AF4, AF5q31, and ENL
associate in an endogenous higher-order complex (hereafter
referred to as ‘‘AEP’’ for the AF4 family/ENL family/P-TEFb
complex) containing P-TEFb in hematopoietic lineage cells.
Leukemogenic Fusion Proteins Inappropriately Tether
AEP Components with MLL
Co-IP analyses were performed to determine whether MLL
chimeric oncoproteins participate in higher-order associations
that recapitulate the composition of AEP. Reciprocal IP using
human leukemia cell lines that express MLL-ENL, MLL-AF4, or
MLL-AF5q31 showed that the respective fusion proteins formCsimilar AEP-like complexes (Figure 1E and Figure S1B).
Conversely, MLL-AF6, an MLL fusion with a cytoplasmic protein
that was not copurified with AF4 or AF5q31, did not coprecipitate
any of the AEP components in ML-2 cells (Figure 1E). Similarly,
wild-type (WT) MLL did not pull down AEP components in
K562 cells while coprecipitating menin, a component of the
MLL complex (Yokoyama et al., 2004) (Figure 1C). Therefore,
the MLL and AEP complexes are separate biochemical entities
that are inappropriately tethered to form MLL/AEP hybrid
complexes by a subset of covalent fusions of MLL in human
leukemia cells.
MLL-ENL and MLL-AF4 Consistently Recruit AEP
Components to MLL Target Genes
Genomic localizations of MLL chimeric proteins and AEP
components were analyzed by chromatin immunoprecipitation
(ChIP) in human leukemia cell lines. Histone marks indicative of
open chromatin states (tri-methyl H3K4 and acetyl H3K9) (Li
et al., 2007) were associated with transcriptionally active loci,
whereas histone marks indicative of closed chromatin (di-methyl
H3K9 and high levels of histone H3) were associated with tran-
scriptionally inactive loci (Figures 2A–2C), verifying the integrity
of ChIP assays. In HB1119 cells, MLL-ENL specifically colocal-
ized with AF4 and AF5q31 at promoter-adjacent regions of the
HOXA9 andMEIS1 genes, which are known to serve critical roles
in MLL-associated leukemogenesis (Ayton and Cleary, 2003;
Nakamura et al., 1996; Wong et al., 2007), whereas the presence
of AEP at non-MLL target loci such as b-ACTIN and GAPDH was
minimal or negligible (Figure 2B and Figure S2A). Similarly, ChIP
analysis showed that AF5q31 and ENL colocalized with endog-
enous MLL-AF4 on the HOXA9 and MEIS1 promoters in
MV4-11 cells (Figure 2C and Figure S2B). Colocalization of
AEP components with MLL oncoproteins was also observed
on other MLL target genes, such as CDKN1B and CDKN2C
(Milne et al., 2005), and the transcribed regions of HOXA9 and
MEIS1 (Figures 2B and 2C), suggesting that MLL/AEP hybrid
complexes may function in transcriptional elongation. Therefore,
a subset of MLL oncoproteins results in consistent recruitment of
AEP components at MLL target chromatin in leukemia cells.
Formation of a Higher Order MLL-AF5q31/AEP Hybrid
Complex Is Required for Sustained Transcription
of Target Genes and Transformation
AF4 and AF5q31 share extensive sequence similarity that
resides in four subregions of the respective proteins (Figure 3A).
A structure/function analysis (Figures 3B and 3C) revealed
that: (1) P-TEFb interacts with AF4 and AF5q31 via subregion 1,
which contains the N-terminal homology domain (NHD) (Nilson
et al., 1997); (2) strong transactivation activity is conferred by
subregion 2, consistent with previous observations (Prasad
et al., 1995; Ma and Staudt, 1996; Morrissey et al., 1997); (3)
ENL interacts with AF4 and AF5q31 through subregion 3 that
encompasses the AF9 interaction domain (Srinivasan et al.,
2004; Zeisig et al., 2005); and (4) the C-terminal homology
domain (CHD) within subregion 4 mediates hetero-association
of AF4 and AF5q31, which appears to be highly preferred over
their respective homo-dimerization (Figure 3B). Preferential
hetero-dimerization was also observed in co-IP experiments
of endogenous or transfected MLL-AF5q31 (Figure 1E andancer Cell 17, 198–212, February 17, 2010 ª2010 Elsevier Inc. 199
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Figure 1. Heterologous Associations of Wild-Type and Oncogenic AF4 and ENL Family Proteins
(A) The scheme used for purification of the AF4 complex.
(B) A silver-stained image shows the proteins immuno-purified using anti-AF4 antibody and subsequently identified by mass spectrometry, as indicated by
arrows on the right. Anti-GST antibody served as a negative control.
(C) K562 nuclear extracts were analyzed by IP western blotting. IP was performed with the antibodies indicated on the top, and the precipitates were immuno-
blotted with the antibodies indicated on the right. Anti-GST and anti-FLAG antibodies served as negative controls. Asterisks indicate signals from IgG used for IP.
(D) Selected fractions from gel filtration analysis of K562 nuclear extracts were analyzed by western blotting for AF4-associated factors (PARP served as a nega-
tive control). Molecular weight standards are shown on the top. A cartoon of a putative AEP complex is depicted. C9, CDK9; cyc T1, cyclin T1.
(E) IP western blot analysis was performed as in (C) on human leukemia cell lines that harbor MLL chromosomal translocations and express MLL chimeric
oncoproteins (indicated at tops). Cartoons of putative MLL fusion complexes are depicted below. See also Figure S1.
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AEP Complex in MLL-Associated LeukemiaFigure S3A), as well as an interaction assay based on GAL4-
dependent transactivation (Figure S3B).
MLL fusion proteins containing the respective subregions of
AF4 or AF5q31 were assessed for their oncogenic potentials in
a myeloid progenitor transformation assay (Figure 3D) (Lavau
et al., 1997). Only MLL-AF5q31 constructs containing subregion
4 (MLL-AF5-4 and MLL-AF5-34) induced serial replating activity
and up-regulation of Hoxa9 transcription (Figures 3E and 3F).
This result indicates that none of the single functions (i.e.,
P-TEFb recruitment, transactivation, or association with ENL)
is sufficient for transformation but rather CHD-mediated associ-
ation with endogenous AEP is required. The corresponding MLL-
AF4-4 and MLL-AF4-34 proteins were not stably expressed and
thus unable to be evaluated (Figure 3F). Although recruitment of
Enl was not sufficient for MLL-AF5q31-dependent transforma-200 Cancer Cell 17, 198–212, February 17, 2010 ª2010 Elsevier Inc.tion, Enl was required because its knockdown by sh-RNA
substantially decreased the clonogenicity andHoxa9 expression
of MLL-AF5q31-transformed cells (Figures 3G–3J). This pheno-
type was rescued by exogenous expression of human ENL, thus
verifying the target specificity of the sh-RNA. Hence, formation of
a higher order MLL/AEP hybrid complex on target genes is
necessary for MLL-AF5q31-dependent transformation.
Transforming Properties of MLL-ENL and MLL-AF9
Correlate with Association with AF4 Family
Proteins and DOT1L
A similar structure/function analysis of MLL-ENL demonstrated
that C-terminal ENL residues (494–559) are required for the inter-
action with AF5q31 (Figures 4A and 4B). This region, which is
evolutionally conserved with AF9 and Saccharomyces cerevisiae
0 
20
40
60
80
100
120
140
20
40
60
80
100
120
0 
0 
20
40
60
80
100
120
140
0 
20
40
60
80
100
120
0 
20
40
60
80
100
120
140
0 
20
40
60
80
100
120
0 
20
40
60
80
100
120
0 
20
40
60
80
100
120
140
20
40
60
80
100
120
0 
0 
20
40
60
80
100
120
0 
20
40
60
80
100
120
140
0 
20
40
60
80
100
120
140
0 
20
40
60
80
100
120
0 
20
40
60
80
100
120
140
0 
20
40
60
80
100
120
140
0 
20
40
60
80
100
120
140
0 
20
40
60
80
100
120
140
0 
20
40
60
80
100
120
1 2 3 4 5 6
1 2 3 4 5 6
1 2 3 4 5 6
1 2 3 4 5 6
1 2 3 4 5 61 2 3 4 5 61 2 3 4 5 6 7 8 9 10 1 2 3 4 5 6 7 8 9 10
0 
20
40
60
80
100
120
140
AR
P1
 
pr HOXA9
2 3 54 6
MEIS1
1 2 3 4 5 6
1 2 3 4 5 6
1 2 3 4 5 6
1 2 3 4 5 6
0 
20
40
60
80
100
120
140
AR
P1
 
pr
H
O
XA
6 
pr
H
O
XA
7 
pr
H
O
XA
9 
pr
CD
KN
1B
 p
r
CD
KN
2C
 
pr
M
EI
S1
 
pr
M
EI
S2
 
pr
G
AP
DH
 
pr
HB1119 (MLL-ENL)
MLLN (mmN4)
MLLN (rpN1)
menin
MV4-11 (MLL-AF4)C
AF4
AF5q31
ENL
H3
H3K9me2
1 2 3 4 5 6 7 8 9 10
1 2 3 4 5 6 7 8 9 10
1 2 3 4 5 6 7 8 9 10
1 2 3 4 5 6 7 8 9 10
1 2 3 4 5 6 7 8 9 10
1 2 3 4 5 6 7 8 9 10
1 2 3 4 5 6 7 8 9 10
1 2 3 4 5 6 7 8 9 10
β
a
ct
in
 
pr
B
0 
20
40
60
80
100
120
HB1119 MV4-11 ML-2 U937 plat-E HAL-01 REH 
ARP1
HOXA6
HOXA7
HOXA9
CDKNIB
CDKN2C
MEIS1
MEIS2
β-actin
R
el
at
iv
e 
ex
pr
es
sio
n 
[%
] A
MLL/menin
AEP
RNAP II 
Open marks
Closed marks
RNAPII
p-RNAPII
H3K79me2
H3K4me3
H3K9ac
MLL-AF4/AEP complexMLL-ENL/AEP complex
R
el
at
iv
e 
oc
cu
pa
nc
y 
[%
] 
HOXA9
2 3 54 6
MEIS1
AR
P1
 
pr
AR
P1
 
pr
H
O
XA
6 
pr
H
O
XA
7 
pr
H
O
XA
9 
pr
CD
KN
1B
 
pr
CD
KN
2C
 
pr
M
EI
S1
 
pr
M
EI
S2
 
pr
G
AP
DH
 
pr
β
a
ct
in
 
pr
MLL target
(active)
Non-MLL 
target
(active)
Not 
active
MLL target
(active)
Non-MLL 
target
(active)
Not 
active
menin
LEDGF
cyc T1
C9
ENL
AF4/5q31
MLL MLL
menin
LEDGF
AF4
ENL
AF5q31
cyc T1
C9
Figure 2. Colocalization of MLL Fusion Proteins and AEP Components on Chromatin
(A) Relative expression of various genes (indicated on the right) in seven human cell lines was analyzed by quantitative RT-PCR. Expression levels were normalized
toGAPDHand are depicted relative to the highest value among the seven cell lines arbitrarily set as 100. Error bars represent standard deviations of triplicate PCRs.
(B) Genomic localizations of various proteins in HB1119 cells were determined by ChIP assay. Cross-linked chromatin was immunoprecipitated with antibodies
specific for the indicated proteins and analyzed by quantitative PCR using primer/probe sets that target promoter-adjacent regions or other genomic regions
indicated at the bottom. Occupancies are displayed relative to the highest value in the group arbitrarily set as 100. Error bars represent standard deviations of
triplicate PCRs. Genes expressed more than 20% of the highest levels in (A) are defined as active genes.
(C) A comparable analysis as in (B) was performed for MV4-11 cells, which harbor a t(4;11) translocation and express MLL-AF4 proteins. The purple rectangle
highlights a locus on which dimethyl H3K79 marks were absent, but the MLL-AF4/AEP complex was present. See also Figure S2.
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AEP Complex in MLL-Associated LeukemiaAnc1 (designated AHD: Anc1 homology domain), displayed
transactivation potential that correlated with association with
AF4 family proteins (Figure 4C). The AHD of ENL also mediated
association with DOT1L (Figure 4D), consistent with results of
previous studies (Mueller et al., 2007). Mutations of MLL-ENL
that abolished AF5q31 and DOT1L interaction (including a single
L550E point mutation) resulted in failure to up-regulate Hoxa9
transcription and transform myeloid progenitors (Figures 4E–
4G). Similarly, the portion of AF9 retained in MLL-AF9 oncopro-
teins, which includes AHD (residues 502–568) (Figure 4A),
mediated AF5q31 and DOT1L association and conferred
GAL4-dependent transactivation, MLL-dependent Hoxa9
expression, and myeloid transformation (Figures 4B–4G).
Unlike MLL-AF5q31-transformed cells, MLL-ENL- and MLL-
AF9-transformed cells did not require WT Enl because their clo-
nogenicities were unaffected by its knockdown (Figures 3I and
3J), consistent with the observation that MLL-ENL did not form
a complex with WT ENL in HB1119 cells (Figure 1E). These
results suggest that association with AF4 family proteins and/or
DOT1L is required for the oncogenic properties of MLL-ENL and
MLL-AF9.
Interactions of ENL with DOT1L or AF4 Family Proteins
Are Mutually Exclusive
To determine whether ENL can simultaneously coassociate with
AF4 family proteins and DOT1L, IP analysis was performed on
cells transiently expressing ENL, AF5q31, and DOT1L. Although
ENL coprecipitated both AF5q31 and DOT1L, the latter two did
not pull down each other (Figure 5A), indicating that the three
proteins do not form a trimeric complex. Similarly, GAL4-AF5-3
effectively coprecipitated ENL but not DOT1L under conditions
where GAL4-ENL successfully pulled down DOT1L (Figure S4).
These data demonstrate that the associations of ENL family
proteins with AF4 family proteins or DOT1L are mutually exclu-
sive. Therefore, the ENL/DOT1L complex is a separate entity
from AEP (Figure 5B).Figure 3. Formation of an AEP-Like Complex Is Required for MLL-AF5
(A) The structures of AF4 and AF5q31 are schematically illustrated. Subregions (1
indicate the sites of fusion with MLL in human leukemia oncoproteins (Jansen et
(B) The four subregions fused to GAL4 DNA binding domain were expressed in 2
[AF4(m) or AF5q31(m)] (lower two panels) and analyzed by IP western blotting. IP a
indicated on the right. (f)GAL4 fusions and myc-tagged AF4 family proteins were
(C) Transactivation activity of respective GAL4 fusions was analyzed using the re
licate analyses.
(D) The experimental scheme of myeloid progenitor transformation assays to eval
which CFU (colony forming unit) activity or Hoxa9 expression was examined.
(E) The structures of various MLL-AF4/AF5q31 mutants and their associated func
and displayed relative to MLL-AF5-34-transduced cells arbitrarily set at 100%. E
triplicate PCRs (right). N.A., not applicable because of unstable expression of M
(F) Protein levels of respective MLL mutants in virus-packaging cells were examin
proteins were not stably expressed.
(G) The experimental scheme to evaluate the effect of Enl knockdown on MLL tr
(H) Transduced myeloid progenitors were analyzed by western blotting with
MLL-AF5q31 and human (X)ENL, respectively.
(I) The clonogenic potentials of MLL-AF5-34-transformed cells transduced with
(vector or sh-Enl). MLL-ENL- or MLL-AF9-transformed cells were also subjected
vector control arbitrarily set as 100. Error bars represent standard deviations of
(J) Cells from first-round colonies following sh-RNA transduction (vector or sh-Enl)
sion levels were normalized to Gapdh and displayed relative to the vector/vector
triplicate PCRs. See also Figure S3.
CRecruitment ofAEP, versusDOT1L,Plays aPredominant
Role in MLL-Dependent Leukemogenesis
The ability of MLL-ENL to associate with AF4 family proteins or
DOT1L raised the issue of which interaction (MLL-ENL/AEP vs.
MLL-ENL/DOT1L) is essential for leukemic transformation (Fig-
ure 5B). To address this issue, an artificial MLL fusion with
DOT1L (MLL-DOT1L) thatdoes notassociatewithAF4 (Figure5C)
but retains the HMT catalytic domain (thus mimics the MLL-ENL/
DOT1L complex) was assessed for its transformation potential.
MLL-DOT1L failed to sufficiently activate Hoxa9 expression to
immortalize myeloid progenitors (Figures 5D and 5E), despite
the comparable levels of protein expression in packaging cells
(Figure 5F) and mRNA expression in first-round colonies (Fig-
ure 5E). In the same experimental condition, MLL-AF5q31
successfully transformed myeloid progenitors (Figure 5E) without
being able to directly associate with DOT1L (Figure 5C). These
results, which contrast with those of previous studies (Okada
et al., 2005), indicate that simple recruitment of DOT1L
HMT activity alone to MLL target genes is not sufficient for
transformation and support a more predominant role for AEP
recruitment.
Nevertheless, DOT1L-dependent H3K79 methylation colocal-
ized with the presence of MLL-ENL at all target loci tested in
HB1119 cells (Figure 2B), indicating that not only AEP compo-
nents but also DOT1L is consistently recruited by MLL-ENL. In
MV4-11 cells, H3K79 methylation marks also colocalized at
most of the MLL-AF4-occupied loci, consistent with previous
observations (Krivtsov et al., 2008; Guenther et al., 2008), despite
the apparent inability to directly recruit DOT1L (Figures 2C and
5C). However, the signal intensities of H3K79 dimethylation
were relatively low at MLL-AF4-target loci, compared with those
at MLL-ENL-target loci (compare relative intensities to those of
b-ACTIN and GAPDH, which served as internal standards)
(Figures 2B and 2C; Figure S2) and were minimal at the CDKN2C
promoter in spite of the localization of abundant AEP compo-
nents (Figure 2C, purple rectangle). Thus, DOT1L-dependentq31-Dependent Myeloid Transformation
–4) of AF4 and AF5q31 are indicated with associated functions. Upward arrows
al., 2005) (A9ID, AF9 interaction domain; Srinivasan et al., 2004).
93T cells (upper four panels) or coexpressed with myc-tagged AF4 or AF5q31
ntibodies are indicated on the left and proteins detected by western blotting are
visualized with anti-FLAG and anti-myc antibodies, respectively.
porter gene shown below. Error bars represent standard deviations from trip-
uate the oncogenic potentials of various MLL mutants shows the time points at
tions are summarized schematically. Hoxa9 levels were normalized to Gapdh
rror bars represent standard deviations of three independent analyses (left) or
LL fusion proteins.
ed by western blotting with anti-MLLN antibody. MLL-AF4-4 and MLL-AF4-34
ansformation is shown schematically. (X)ENL, Xpress-tagged human ENL.
anti-MLLN (top) and anti-Xpress (bottom) antibodies to detect exogenous
or without (X)ENL are shown at the second plating after sh-RNA transduction
to sh-RNA transduction for comparison. CFUs are expressed relative to the
three independent analyses.
were analyzed by RT-PCR for expression of endogenousEnl orHoxa9. Expres-
control cells arbitrarily set at 100. Error bars represent standard deviations of
ancer Cell 17, 198–212, February 17, 2010 ª2010 Elsevier Inc. 203
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Figure 4. MLL-ENL andMLL-AF9 TransformMyeloid Progenitors via the AHD, which Is Responsible for Association with AF4 Family Proteins
and DOT1L
(A) The structures of ENL and AF9 are schematically illustrated with associated functions (Zeisig et al., 2005). Aligned amino acid sequences for the minimum
transformation domain are also shown with the positions of deletion or substitution mutations and AHD. Upward arrows indicate the sites of fusion with MLL
in human leukemia oncoproteins (Jansen et al., 2005).
(B) Domain mapping of ENL family proteins for association with AF5q31 was performed with FLAG-tagged GAL4 fusion constructs of ENL (372–559 aa) and AF9
(478–568 aa). IP was performed with anti-GAL4 antibody, and the precipitates were immunoblotted with anti-FLAG antibody for (f)GAL4 fusions or anti-AF5q31
antibody for endogenous AF5q31.
(C) Transactivation activity of indicated GAL4 constructs was analyzed by luciferase assay as in Figure 3C.
(D) The same set of GAL4 fusion proteins used in (B) and HA-tagged DOT1L [DOT1L(H)] were coexpressed in 293T cells and analyzed by IP western blotting.
IP was performed with anti-FLAG antibody and the precipitates were immunoblotted with anti-HA antibody.
(E) The experimental scheme is shown for myeloid progenitor transformation assays to evaluate the oncogenic potentials of MLL mutants.
(F) The structures of MLL-ENL and MLL-AF9 mutants and their associated functions are summarized with schematic representations. Hoxa9 expression levels
were normalized toGapdh and displayed relative to theMLL-ENL-transduced cells arbitrarily set at 100%. Error bars represent standard deviations of three inde-
pendent analyses (left) or triplicate PCRs (right). N.A., not applicable because of unstable expression of MLL fusion proteins. The asterisk indicates that asso-
ciation of ENL D548–559 mutant with DOT1L was detected but reduced substantially, compared with WT ENL.
(G) Protein levels of respective MLL mutants in virus packaging cells were examined by western blotting with anti-MLLN antibody. MLL-ENL D523–547 was not
stably expressed.
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Figure 5. Associations of ENL Family Proteins with AF4 Family Proteins or DOT1L Are Mutually Exclusive
(A) AF5q31(m), (X)ENL, and DOT1L(H) were coexpressed in 293T cells and analyzed by IP western blotting. IP was performed with antibodies indicated on the top,
and the precipitates were immunoblotted with anti-myc, anti-Xpress, or anti-HA antibody.
(B) Putative conformations of various ENL complexes are shown schematically. ENL forms two distinct complexes: AEP and ENL/DOT1L. Similarly, MLL-ENL
participates in two mutually exclusive associations to form the MLL-ENL/AEP and MLL-ENL/DOT1L complexes that are approximate to the MLL-AF5q31/
AEP and MLL-DOT1L complexes, respectively.
(C) FLAG-tagged MLL fusion proteins [(f) MLL fusions] were coexpressed with AF4(m) or DOT1L(H) in 293T cells and were analyzed by IP western blotting. IP was
performed with anti-FLAG antibody, and the precipitates were immunoblotted with anti-MLLN, anti-myc, or anti-HA antibody.
(D) The experimental scheme is shown for myeloid progenitor transformation assays to evaluate the oncogenic potentials of MLL mutants.
(E) The structures of MLL-fusion proteins and their associated functions are summarized. Expression of MLL fusion genes or Hoxa9 was examined by RT-PCR in
first-round colonies. Expression levels were normalized to Gapdh levels and are displayed relative to the transcript levels in MLL-ENL-transduced cells arbitrarily
set at 100. Error bars represent standard deviations of three independent analyses (left) or triplicate PCRs (middle and right). HMT, histone methyltransferase
catalytic domain; EBD, ENL binding domain (Okada et al., 2005; Mueller et al., 2007).
(F) Protein levels of MLL fusions in virus packaging cells were analyzed by western blotting with anti-MLLN antibody. See also Figure S4.
Cancer Cell
AEP Complex in MLL-Associated LeukemiaH3K79 methylation is associated with the presence of the MLL-
AF4/AEP-hybrid complex, but the two distinct biochemical enti-
ties are not constitutively coupled. These results suggest that
DOT1L is functionally linked to MLL-AF4 but normally recruited
to target loci subsequent to AEP components.CAEP Is Indirectly Recruited to MLL-AF6-Occupied Loci
to Sustain Transcription and Transformation
To investigate whether AEP involvement is restricted to MLL
fusions with AF4 and ENL family proteins, ChIP analyses were
performed on ML-2 cells. Surprisingly, MLL-AF6 colocalizedancer Cell 17, 198–212, February 17, 2010 ª2010 Elsevier Inc. 205
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Figure 6. Indirect Recruitment of AEP to MLL-AF6- or WT MLL-Occupied Loci
(A and B) Genomic localizations of indicated proteins in ML-2 (A) and U937 (B) cells were determined by ChIP assay as in Figure 2B. The purple rectangle high-
lights regions where AEP is absent while the MLL complexes are present. ChIP data using anti-MLLN (rpN1) and anti-menin antibodies are partially adapted from
a previous report (Yokoyama and Cleary, 2008). See also Figure S5.
Cancer Cell
AEP Complex in MLL-Associated Leukemiawith AEP at the chromatin of MLL target genes (HOXA7, HOXA9,
CDKN1B, and CDKN2C) (Figure 6A and Figure S5A) despite its
inability to directly associate with AEP (Figures 1E and 5C). The
occupancies of CDK9 and phosphorylated RNAPII coincided206 Cancer Cell 17, 198–212, February 17, 2010 ª2010 Elsevier Inc.with the presence of AEP on MLL-AF6 target genes
(Figure 6A). Characteristically, high levels of dimethyl H3K79
were associated with the presence of AEP, corroborating the
functional link between AEP and DOT1L. These results suggest
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Figure 7. ENL Is Required for MLL-AF6-Dependent Transactivation and Transformation
(A) The experimental scheme to evaluate the effect of Enl knockdown on MLL transformation is shown.
(B) Clonogenic potentials are shown for myeloid cells transformed by MLL oncogenes (indicated below) at the second plating after sh-RNA transduction (vector or
sh-Enl). CFU numbers are displayed relative to the vector control arbitrarily set as 100. Error bars represent standard deviations of three independent analyses.
(C) MLL-AF6-transformed cells from first- and second-round colonies following sh-RNA transduction (vector or sh-Enl) were analyzed by RT-PCR for expression
of endogenous Enl orHoxa9. Expression levels were normalized toGAPDH levels and are displayed relative to the transcript levels in vector control cells arbitrarily
set as 100. Error bars represent standard deviations of triplicate PCRs.
(D) The same analysis as (C) was performed on MLL-ENL-transformed cells. Note that data in (B) and (D) are partially redundant with Figures 3I and 3J.
Cancer Cell
AEP Complex in MLL-Associated Leukemiathat the AEP complex can be recruited to MLL target loci via an
indirect mechanism potentially serving a role in MLL-AF6-
dependent leukemogenesis.
MLL-AF6-transformed cells were also dependent on Enl,
because its knockdown reduced their clonogenicity and Hoxa9
expression by 50% (Figures 7A and 7C). This was less severe,
compared with MLL-AF5q31-transformed cells (Figure 7B), in
part because of insufficient knockdown by the sh-RNA, since
secondary colonies expressed Hoxa9 at its normal levels
accompanied with impaired knockdown of Enl (Figure 7C), indi-
cating a selective proliferative advantage of cells in which Enl
was incompletely knocked down (MLL-ENL served as a negative
control in Figure 7D). Thus, transformation by MLL-AF6 is depen-
dent on ENL, despite an inability to directly associate with AEP.
AEP Facilitates the Physiologic MLL-Dependent
Transcriptional Pathway
The foregoing results prompted studies of a potential relation-
ship of AEP in physiologic transcriptional regulation by WT
MLL. ChIP analyses of U937 cells, which lack an MLL chromo-
somal translocation (Dreyling et al., 1996; Guenther et al.,
2005), showed that AEP colocalized with WT MLL at the
HOXA9, MEIS1, and CDKN1B promoters (Figure 6B and
Figure S5B). However, in contrast to MLL leukemia cell lines, co-
localization was not observed at all of the MLL-occupied loci in
U937 cells. For instance, the MLL complex occupied both the
HOXA7 and HOXA9 loci, whereas AEP associated only with
the latter (Figure 6B, purple rectangle). A similar disparity was
observed at the CDKN2C promoter. These results suggest that
AEP is recruited to WT MLL-occupied loci in a context-depen-
dent manner, as opposed to its constitutive recruitment in MLL
leukemia cells. The presence of AEP correlated more closely
with active transcriptional marks such as phospho-RNAPII
and acetyl-histone H3K9 (e.g., the HOXA7-9 locus), suggestingCthat AEP recruitment to MLL-targeted chromatin facilitates
transcription.
The role of ENL in physiologic MLL-dependent transcriptional
maintenance was assessed by knocking down Enl in mouse
embryonic fibroblasts (MEFs), in which Hoxc8 is a target gene
of the Mll/menin complex (Figure 8A) (Hughes et al., 2004; Milne
et al., 2002). Enl knockdown caused reduction of Hoxc8
expression, which could be prevented by antecedent expression
of exogenous human ENL (Figure 8B). Thus, Enl is required
for physiologic transcriptional regulation by the Mll/menin
complex. Moreover, Dot1l-mediated histone methylation was
decreased at the Hoxc8 promoter inMen1 null MEFs (Figure 8C),
indicating that the MLL/menin complex functions upstream of
ENL/DOT1L functions.
Furthermore, ENL knockdown in U937 cells caused down-
regulation of HOXA9, CDKN1B, and MEIS1, whose genomic
loci were occupied by both MLL and AEP complexes, but did
not affect expression of genes occupied by the MLL complex
without AEP (HOXA7 and CDKN2C) (AF5q31, MLL, or b-ACTIN
served as negative controls) (Figures 6B and 8D). Thus, ENL is
specifically required for the optimal transcription of genes occu-
pied by both MLL and AEP complexes.
DISCUSSION
Our biochemical purification of AF4 family proteins demon-
strates that they normally associate with ENL and the P-TEFb
elongation factor in an endogenous complex (AEP) in hemato-
poietic cells. MLL oncoproteins fused with AEP components
(AF4 or ENL family proteins) nucleate formation of MLL/AEP
hybrid complexes that constitutively occupy MLL-target chro-
matin. This aberrant recruitment of AEP components causes
sustained activation of MLL target gene transcription and trans-
formation of hematopoietic progenitors. Although the AEP andancer Cell 17, 198–212, February 17, 2010 ª2010 Elsevier Inc. 207
(1) Bypassed by fusion with AEP 
     (e.g. MLL-AF4, MLL-ENL)
(2) Bypassed by indirect recruitment
     of AEP (e.g. MLL-AF6)
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Figure 8. ENL Functions Downstream of Physiologic MLL-Dependent Transcriptional Pathways
(A) Expression levels of Enl and Hoxc8 in WT or Men1/ MEFs were determined by RT-PCR (normalized to b-actin levels and are displayed relative to the vector
control arbitrarily set as 100). Error bars represent standard deviations of triplicate PCRs.
(B) Expression of Enl and Hoxc8 with or without Enl knockdown/rescue was determined by RT-PCR. Expression levels were normalized to b-actin levels and are
expressed relative to the vector/vector control arbitrarily set as 100. Error bars represent standard deviations of triplicate PCRs. Protein levels of the exogenously
expressed (X)ENL (right panels) were assessed by western blotting with an anti-Xpress antibody (actin immunoblot served as a loading control). nsp, nonspecific
band.
(C) ChIP assay was performed on WT orMen1/ MEFs using anti-dimethyl H3K79 and histone H3 antibodies for theHoxc8 promoter-adjacent region and results
displayed as relative ratio (%) to the input DNA. Error bars represent standard deviations of triplicate PCRs.
(D) The effects of ENL-knockdown are shown for two different sh-RNAs in U937 cells. Expression of various genes was analyzed by RT-PCR 4 days after trans-
duction/puromycin selection. Expression values were normalized to GAPDH levels and displayed relative to the vector control arbitrarily set as 100. Error bars
represent standard deviations of triplicate PCRs.
(E) A three-step model of MLL-dependent transcription.
Cancer Cell
AEP Complex in MLL-Associated LeukemiaMLL complexes are normally separate biochemical entities, our
studies support a dependent role for the AEP complex in physi-
ologic MLL target gene expression pathways, whose conditional
recruitment mechanisms are often bypassed by leukemic MLL
fusion proteins.
The AEP complex purified from leukemia cell lines under our
experimental conditions contained ENL as an integral compo-208 Cancer Cell 17, 198–212, February 17, 2010 ª2010 Elsevier Inc.nent but lacked a number of previously reported ENL-associated
proteins, most notably the DOT1L histone methyltransferase
(Mueller et al., 2007). Our domain-mapping analyses provide
a molecular basis for its absence in that DOT1L and AF4 family
proteins use the same binding surface within the AHD of ENL.
Because of this physical constraint, DOT1L and AF4 family
proteins are incapable of simultaneously associating with the
Cancer Cell
AEP Complex in MLL-Associated LeukemiaAHD to form an AF4/ENL/DOT1L trimeric complex. Therefore,
retention of DOT1L in the AF4 complex previously identified in
thymus homogenates (Bitoun et al., 2007) is likely mediated by
other proteins (e.g., AF10 and RNAPII) but not by ENL/AF9.
Our data suggest that an endogenous ENL/DOT1L complex
and AEP normally exist as separate entities consistent with
previous suggestions that ENL may participate in a mixture of
different subcomplexes (Mueller et al., 2007).
A role for ENL in multiple subcomplexes raises the issue of
which of its molecular interactions is essential for MLL leukemo-
genesis. This issue was addressed by assessing the oncogenic
potential of MLL fused with the DOT1L catalytic domain, which
effectively bypasses ENL. Contrary to a previous report (Okada
et al., 2005), MLL-DOT1L was not sufficient for transactivation
of MLL target genes and transformation of myeloid progenitors
under our experimental conditions that read out the oncogenic
properties of MLL-AF5q31 and MLL-ENL. This finding indicates
that aberrant recruitment of AEP, not DOT1L, plays a primary
rate-limiting role in transactivation and transformation by MLL
fusion proteins, a conclusion further supported by structure/
function analysis of MLL-AF5q31 showing that its CHD, which
mediates hetero-interactions with AF4 family members, was
necessary and sufficient for transformation.
Nevertheless, ChIP analyses by us and others show that
H3K79 methylation marks are present at most MLL-AF4-target
loci (Figure 2B) (Krivtsov et al., 2008; Guenther et al., 2008), indi-
cating that there is a strong functional interconnection between
AEP and DOT1L. DOT1L-dependent H3K79 methylation is asso-
ciated with transcribed regions and stimulated by histone H2B
K120 mono-ubiquitination (a histone mark accompanied with
transcription), but is not required for transcription itself (Steger
et al., 2008; McGinty et al., 2008). This finding suggests that
DOT1L-dependent H3K79 methylation occurs after the traverse
of RNAPII and may play roles in the maintenance of transcrip-
tional memory rather than initiating transcription per se. In this
context, our studies support dual roles for ENL, which is capable
of interacting with AEP or DOT1L through its AHD to sequentially
recruit them to the same target chromatin, possibly via its
N-terminal YEATS domain that retains a chromatin binding
property (Zeisig et al., 2005).
Our data demonstrate that AEP colocalizes with WT MLL on
target promoters indicative of a role in physiologic as well as
oncogenic MLL-dependent transcriptional pathways. Support-
ing this notion, knockdown of ENL impaired expression of MLL
target genes in MEFs and U937 cells (Figures 8B and 8D), and
Af9-deficient mice display homeotic transformations similar to
those of Mll-deficient mice (Collins et al., 2002). The recruitment
of AEP to MLL-target loci appears to be nonconstitutive because
some MLL-occupied loci do not contain AEP (Figure 6B).
Because the presence of the MLL complex does not invariably
correlate with occupancy by AEP, other factors or signals yet to
be identified are likely required for AEP recruitment. On the basis
of these observations and speculations, we propose a three-step
model in which WT MLL first establishes/maintains the transcrip-
tionally poised state (Step 1), AEP is then recruited to facilitate
onset of transcriptional initiation and/or elongation (Step 2),
which is followed by DOT1L-dependent H3K79 methylation post-
transcription (Step 3) (Figure 8E). In this model, ENL serves a key
role in sequential recruitment of AEP and DOT1L, respectively.CTo date, up to 50 different proteins have been reported to fuse
withMLL in human leukemias. This promiscuity poses a question
as to whether any common trait is shared among the fusion
partners. We demonstrate here that AEP recruitment is a down-
stream event in physiologic MLL-dependent transcriptional
pathways and is regulated in a context-dependent manner.
MLL-AF4 and MLL-ENL family fusions transform myeloid
progenitors by constitutively recruiting AEP to MLL-target loci
through direct association. Thus, one of the major mechanisms
of MLL-dependent transformation is constitutive activation of
MLL-dependent transcription by direct recruitment of AEP,
which circumvents the regulatory mechanisms that normally
control AEP recruitment (Figure 8E).
AEP does not physically interact with MLL-AF6, but neverthe-
less consistently colocalizes with MLL-AF6 at target chromatin
to activate transcription (Figures 6A and 8E). Although the
mechanism of this aberrant AEP recruitment is unknown, it indi-
cates that AEP serves an even broader role in MLL leukemogen-
esis beyond the subset of fusions with AEP components.
Determination of whether this role may extend to other MLL fusion
proteins requires further investigation. Nevertheless, our studies
show that most of the frequently occurring MLL fusions (e.g.,
MLL-AF4, MLL-AF9, MLL-ENL, and MLL-AF6) use a similar
strategy for leukemic transformation, in which AEP is constitu-
tively recruited to MLL target genes either directly or indirectly.
A critical role for AEP in MLL-mediated leukemic transforma-
tion suggests that it may be an ideal target for molecular therapy
of MLL-associated leukemias. In this regard, our results tenta-
tively support the rationale for CDK9 inhibition as a potential ther-
apeutic strategy, or inhibition of DOT1L whose activity appears
to be functionally linked to AEP and possibly plays important
roles in the maintenance of the epigenetic status of target genes.
However, these molecules are likely to have more generalized
roles other than AEP-dependent transcription (Jones et al.,
2008; Peterlin and Price, 2006); therefore, serious side effects
might occur if they are effectively inhibited. Thus, compounds
that specifically target the function of AF4- and ENL family
proteins but not P-TEFb or DOT1L may selectively inhibit MLL-
dependent transcription and benefit the treatment of MLL-asso-
ciated leukemias.
EXPERIMENTAL PROCEDURES
Monoclonal Antibodies
Highly specific monoclonal antibodies were generated against MBP fusion
proteins containing portions of human AF4 (aa 782–979) (clone 2C.1), human
AF5q31 (aa 489–680) (clone 1.3), and human ENL (414–472) (clone 3.1),
respectively.
Cell Culture
Human leukemia cell lines K562, HB1119, SEM-K2, KP-L-RY, ML-2, MV4-11,
and U937 were cultured in RPMI 1640 medium supplemented with 15% fetal
calf serum and nonessential amino acids. MEFs were prepared from E11.5 p53
null embryos. The 293T and plat-E cell lines and MEFs were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 15% fetal
calf serum and nonessential amino acids.
Purification of the AEP Complex, Immunoprecipitation,
and Western Blotting
The purification procedure for AEP is described in the Supplemental
Experimental Procedures. Immunoprecipitation and western blotting methodsancer Cell 17, 198–212, February 17, 2010 ª2010 Elsevier Inc. 209
Cancer Cell
AEP Complex in MLL-Associated Leukemiaare described elsewhere (Yokoyama et al., 2004; 2005). Primary anti-
bodies used in this study are summarized in the Supplemental Experimental
Procedures.
Quantitative RT-PCR
Reverse transcription and quantitative PCR were performed as described
elsewhere (Yokoyama et al., 2005; Yokoyama and Cleary, 2008) using Taqman
probes purchased from Applied Biosystems. The details of the probe set are
summarized in the Supplemental Experimental Procedures. Expression levels
(average values and standard deviations of triplicate determinations) normal-
ized to housekeeping genes such as GAPDH and b-ACTIN were calculated
using a standard curve and the relative quantification method as described
in ABI User Bulletin #2.
Chromatin Immunoprecipitation Assay
Chromatin immunoprecipitations were performed as described elsewhere
(Weinmann and Farnham, 2002; Yokoyama and Cleary, 2008). Primary anti-
bodies used in ChIP assays are summarized in Supplemental Experimental
Procedures. Quantitative PCR was performed on the precipitated DNAs in
triplicate using primers and probes described in Supplemental Experi-
mental Procedures. The values relative to input were determined using a stan-
dard curve and the relative quantification method as described in ABI User
Bulletin #2.
Vector Construction
cDNA fragments of AF4 and AF5q31 were cloned into pcDNA3.1/myc-His A
(Invitrogen) for expressing c-myc tagged proteins, or pBICEP-CMV-2 (Sigma)
for expressing FLAG-tagged proteins. pMSCV-neo constructs encoding MLL-
ENL, MLL-AF9, and MLL-AF6 were described elsewhere (Ayton and Cleary,
2003; Somervaille and Cleary, 2006). pMSCV-hygro-Xpress tagged ENL and
pMSCV-neo-Xpress tagged MLL-AF5q31-34 were generated by fusing the
Xpress-tag sequence from pcDNA4 HisMax vector with the cDNAs of ENL
or MLL-AF5q31, respectively. Other expression vectors for various MLL
mutants were generated by restriction enzyme digestion or PCR-based muta-
genesis. Various FLAG-tagged MLL fusions were also cloned into pCMV5
vector and used for IP analysis. The expression vectors for FLAG-tagged
GAL4 fusion proteins were constructed by PCR using pM (Clontech) as
template and cloned into pCMV5 vector. The sh-RNA expression vectors tar-
geting murine Enl (TRCN0000084405) and human ENL (TRCN000019291[#1],
TRCN000019293[#2]) were purchased from Open Biosystems.
Virus Production
Ecotropic retrovirus was produced using plat-E packaging cells (Morita et al.,
2000). Lentivirus was produced by cotransfection of 293T cells with viral
vectors and pCMV dR8.74 and pMD.G packaging constructs (Dull et al.,
1998). Supernatant medium containing virus was harvested 48 hr after trans-
fection and was used for transductions.
Myeloid Progenitor Transformation Assay
Myeloid progenitor transformation was assessed as described elsewhere
(Lavau et al., 1997; Yokoyama and Cleary, 2008) using cells harvested from
the femurs of CD45.1 inbred C57BL/6 mice. C-kit-positive cells were enriched
by immunomagnetic selection using an Auto MACS (Miltenyi Biotech), were
transduced with recombinant retrovirus by spinoculation, and were plated in
methylcellulose medium (M3231, StemCell Technologies) containing SCF,
IL-3, IL-6, and GM-CSF. The colony-forming units (CFUs) per 104 plated cells
were quantified after 5–7 days of culture and were expressed as the average
and standard deviation of at least triplicate determinations. For secondary
transductions, 105 cells were transduced with retrovirus by spinoculation,
were cultured in methylcellulose medium overnight, and were selected for
drug resistance (hygromycin 750 mg/ml, puromycin 4 mg/ml) for at least
2 days prior to CFC enumeration.
Transactivation Assay
Transactivation assays were performed using 293T cells as described else-
where (Yokoyama et al., 2002). Cells cultured in 24-well dishes were trans-
fected with 25 ng of pRL-tk, 250 ng of pFR-luc, and 500 ng of pCMV5
FLAG-GAL4 fusion protein vector per well. Cells were lysed 24 hr later and210 Cancer Cell 17, 198–212, February 17, 2010 ª2010 Elsevier Inc.analyzed for luciferase activity using a dual luciferase assay kit according to
the manufacturer’s instructions (Promega). Relative luciferase activities were
normalized to renilla luciferase activities and expressed with the average
values and standard deviations of triplicate determinations relative to the
GAL4 DNA binding domain controls.
SUPPLEMENTAL INFORMATION
Supplemental information includes five figures and Supplemental Experi-
mental Procedures and may be found with this article online at doi:10.1016/
j.ccr.2009.12.040.
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